Section Arrow
ARDX.NASDAQ
- Ardelyx
Quotes are at least 15-min delayed:2024/05/16 00:05 EDT
Last
 7.85
+0.06 (+0.77%)
Day High 
8.05 
Prev. Close
7.79 
1-M High
9.33 
Volume 
2.46M 
Bid
7.86
Ask
7.94
Day Low
7.84 
Open
7.95 
1-M Low
6.23 
Market Cap 
1.82B 
Currency USD 
P/E -- 
%Yield
10-SMA 8.07 
20-SMA 7.25 
50-SMA 7.58 
52-W High 10.13 
52-W Low 3.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.28/-0.07
Enterprise Value
1.87B
Balance Sheet
Book Value Per Share
0.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
124.46M
Operating Revenue Per Share
0.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 00:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.